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Abstract
The PI3K pathway is a major driver of cancer progression. However,
clinical resistance to PI3K inhibition is common. IBL-302 is a novel
highly specific triple PIM, PI3K, and mTOR inhibitor. Screening IBL-
302 in over 700 cell lines representing 47 tumor types identified
neuroblastoma as a strong candidate for PIM/PI3K/mTOR inhibi-
tion. IBL-302 was more effective than single PI3K inhibition
in vitro, and IBL-302 treatment of neuroblastoma patient-derived
xenograft (PDX) cells induced apoptosis, differentiated tumor cells,
and decreased N-Myc protein levels. IBL-302 further enhanced the
effect of the common cytotoxic chemotherapies cisplatin, doxoru-
bicin, and etoposide. Global genome, proteome, and phospho-
proteome analyses identified crucial biological processes, including
cell motility and apoptosis, targeted by IBL-302 treatment. While
IBL-302 treatment alone reduced tumor growth in vivo, combina-
tion therapy with low-dose cisplatin inhibited neuroblastoma PDX
growth. Complementing conventional chemotherapy treatment
with PIM/PI3K/mTOR inhibition has the potential to improve clini-
cal outcomes and reduce severe late effects in children with high-
risk neuroblastoma.
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Introduction
Phosphoinositol-3-kinase (PI3K) activation is a driver in many
cancers (Engelman, 2009). The mammalian target of rapamycin
(mTOR), a downstream PI3K pathway effector, promotes the expres-
sion of proteins involved in cell growth and survival, and mTOR
kinase inhibitors, either alone or in combination with PI3K inhibi-
tors, have shown preclinical promise (Fruman et al, 2017). These
encouraging data have led to clinical trials of small-molecule PI3K
and PI3K/mTOR pathway inhibitors (Fruman et al, 2017).
Neuroblastoma is a childhood malignancy of the sympathetic
nervous system that accounts for 15% of all pediatric cancer fatali-
ties. Children with high-risk disease have poor survival rates, with
up to 40% 5-year mortality. Current treatment strategies include
high-dose chemotherapy, surgery, radiotherapy, and anti-GD2 ther-
apy. We and others have shown that targeting the PI3K/mTOR path-
way could be a viable treatment for aggressive neuroblastoma
(Chesler et al, 2006; Johnsen et al, 2008; Segerström et al, 2011;
Chanthery et al, 2012; Mohlin et al, 2013, 2015; Cage et al, 2015;
Stewart et al, 2015; Vaughan et al, 2016). Several studies reported
anti-tumor effects and improved survival rates in preclinical neurob-
lastoma models using PI3K inhibitors LY294002 (Chesler et al,
2006), PI-103 (Segerström et al, 2011), dactolisib/NVP-BEZ235
(Chanthery et al, 2012; Stewart et al, 2015; Vaughan et al, 2016),
ZSTK474 (Vaughan et al, 2016), PIK-75 (Cage et al, 2015), PW-12
(Cage et al, 2015), BKM120 (Stewart et al, 2015), and/or SF1126
(Erdreich-Epstein et al, 2016). In addition, AKT inhibitor perifosine
(Li et al, 2010, 2011) and mTOR inhibitors rapamycin (Johnsen
et al, 2008), CCI-779 (Johnsen et al, 2008), and Torin (Vaughan
et al, 2016) were demonstrated to decrease proliferation in vitro and
consequent tumor growth in vivo. One explanation to the promising
preclinical results from inhibiting PI3K/AKT/mTOR could be the
anti-angiogenic downstream effects (Johnsen et al, 2008; Chanthery
et al, 2012; Mohlin et al, 2015). The majority of reports also showed
that neuroblastoma cells with high expression of MYCN were more
sensitive to PI3K inhibition and/or that treatment resulted in down-
regulated N-Myc protein levels in vitro and in vivo (Cage et al, 2015;
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Chanthery et al, 2012; Chesler et al, 2006, Erdreich-Epstein et al,
2016, Johnsen et al, 2008; Vaughan et al, 2016). Importantly, the
PI3K inhibitor perifosine has recently been tested in Phase I/Ib clini-
cal trials with promising therapeutic effects and negligible toxicity in
46 neuroblastoma patients (Kushner et al, 2017; Matsumoto et al,
2017).
However, intrinsic resistance and acquired resistance to PI3K
inhibitors are possible major obstacles to effective treatment with
these agents. Resistance mechanisms include activation of down-
stream mTOR complexes and activation of other networked signal-
ing pathways (Elkabets et al, 2013). The serine/threonine proviral
insertion site in murine leukemia virus (PIM) kinases is overex-
pressed in many cancers and is associated with MYC overexpression
and metastasis. Increased PIM1-3 expression has been linked to
PI3K inhibitor resistance (Nawijn et al, 2011; Le et al, 2016). As a
result, we synthesized the IBL-300 series multikinase inhibitors to
specifically target PIM and PI3K to improve efficacy.
Here, we show that PIM, PI3K, and mTOR inhibitor IBL-302
demonstrated robust target specificity. In 707 cell lines across 47
tumor types, neuroblastoma was most sensitive to IBL-302 treat-
ment, and of 16 neuroblastoma cell lines, IBL-302 was generally
more effective than PI3K inhibitors alone. We used neuroblastoma
patient-derived xenografts (PDXs) and cell lines to investigate the
benefit of combination therapies directed toward PIM, PI3K, and
mTOR pathways. Nanomolar concentrations of IBL-302 induced
apoptosis and tumor cell differentiation and reduced N-Myc protein
levels. IBL-302 potentiated the effect of three clinically used
chemotherapeutic agents in vitro and low-dose cisplatin in vivo.
Finally, RNA sequencing and mass spectrometry analyses of IBL-
302-treated PDX cells demonstrated that multitarget treatment
induced apoptosis and cell death while diminishing cell growth and
motility. Adding multikinase PIM/PI3K/mTOR inhibitors to current
treatments to lower administered doses of highly toxic chemother-
apy could decrease complications later in life and improve outcomes
in these young patients.
Results
High PIM3 expression is associated with poor outcome
We first investigated the potential roles of PIM isoforms in neurob-
lastoma. PIM1 and PIM3 were expressed in neuroblastoma cell lines
and PDX-derived cell cultures (Appendix Fig S1A and B). High levels
of PIM1 and PIM3 were also significantly associated with adverse
neuroblastoma patient outcomes [Appendix Fig S1C (PIM1) and D
(PIM3)].
Neuroblastoma is highly sensitive to triple
PIM/PI3K/mTOR inhibition
We then developed single compound multikinase inhibitors directed
toward PIM, PI3K, and mTOR (covered under patent WO2012/
156756). The precise synthetic structures of IBL-301 and IBL-302 are
outlined in Fig 1A and B, respectively. Due to superior pharmaceuti-
cal profile over IBL-301 in vivo, the closely related analog IBL-302
was selected for further development. We also included the previ-
ously published dual PIM/PI3K inhibitor IBL-202 in our studies
(Crassini et al, 2018). Target efficiency toward PI3Ka, mTOR, PIM1,
PIM2, and PIM3 displayed as IC50 (nM) for all three inhibitors is
shown in Fig 1C.
In an initial screen for tumor type sensitivity to triple PIM/PI3K/
mTOR inhibition by IBL-302, 707 cell lines derived from 47 different
tumor types were tested by the Genomics of Drug Sensitivity in
Cancer (GDSC) screening program (Yang et al, 2013). Selecting for
tumor types represented by at least five cell lines, GI50 values for
IBL-302 were compared for the remaining 35 tumor types. Neurob-
lastoma was the most sensitive cancer to IBL-302 treatment
(Fig 2A). To establish whether neuroblastoma sensitivity to IBL-302
was due to triple target inhibition or whether the effects were
conferred by PI3K pathway inhibition, GI50 values were compared
between IBL-302 and the PI3K/mTOR inhibitors dactolisib, PI-103,
and omipalisib, the mTOR inhibitor AZD8055, and the ribosomal S6
kinase (RSK)/PIM inhibitor SL0101 using GDSC data. Across a panel
of 31 tumor types, neuroblastoma did not show particular sensitivity
to any of the five PI3K-specific inhibitors (Appendix Fig S1E–I).
Furthermore, analyzing GI50 values across a panel of 16 neuroblas-
toma cell lines showed that the majority were highly sensitive to
IBL-302 compared with PI3K inhibitors alone (IBL-302 was among
the top-two most sensitive compounds in 14 of the 16 cell lines;
Fig 2B).
Neuroblastoma cells differentiate in response to
PIM/PI3K/mTOR inhibition
To assess the effects of IBL inhibitors, we treated neuroblastoma
PDX cells (Appendix Table S1, and Braekeveldt et al, 2015; Persson
et al, 2017) and conventional neuroblastoma cell lines with increas-
ing drug concentrations surrounding their respective GI50 range
(Appendix Table S2). We first verified that IBL-202 (PIM/PI3K) and
IBL-301 (PIM/PI3K/mTOR) targeted the intended individual signal-
ing pathways. Treatment with the IBL inhibitors downregulated the
levels of phosphorylated Akt (Ser473 and Thr308), phosphorylated
p70S6K and p85S6K (Thr412 and Thr389, respectively), and phos-
phorylated PRAS40 (Thr246; Figs 3A–C and EV1A–C). It has been
suggested that tumors are more susceptible to chemotherapy when
induced into a differentiated state due to the reduction in the stem
cell pool (Pietras et al, 2010). Triple kinase inhibition with IBL-301
initiated profound neurite outgrowth, a morphological sign of
differentiation, in PDX LU-NB-3 cells as well as SK-N-BE(2)c and
SK-N-SH neuroblastoma cell lines (Figs 3D and EV1D). These
results were confirmed by Tuj1 staining and neurite outgrowth
quantification (Figs 3D and E, and EV1E). In addition, gene expres-
sion of the neuronal differentiation marker GAP43 was slightly
upregulated (Fig EV2A), and Gap43 protein expression was induced
in LU-NB-3 PDX and SK-N-BE(2)c cells (Fig 3F).
N-Myc protein expression is downregulated following IBL
inhibitor treatment
Amplification of the MYCN oncogene correlates with aggressive
neuroblastoma growth, and we thus investigated putative correla-
tions between MYCN and PIM isoform expression levels. There were
no differences in PIM1 expression in MYCN-amplified vs. non-ampli-
fied tumors, whereas PIM3 was expressed at significantly higher
levels in MYCN-amplified tumors (Fig EV2B). We therefore
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investigated whether PIM1 and PIM3 had prognostic effects indepen-
dent of MYCN through multivariate analyses. PIM3 expression did
indeed fall out as significant independent prognostic variable in a
multivariate cox regression analysis including MYCN status
(P = 0.007), while PIM1 expression did not (P = 0.084; Fig EV2C).
IBL-202/301 treatment of PDX cells and neuroblastoma cell lines
resulted in unchanged MYCN mRNA levels (Fig EV2D) but
pronounced decreases in N-Myc protein levels (Fig 3G).
Multikinase PIM/PI3K/mTOR inhibition induces neuroblastoma
cell death
Treatment with IBL-202 and IBL-301 reduced cell viability in two
PDX lines and two conventional neuroblastoma cell lines, and the
triple PIM/PI3K/mTOR inhibitor IBL-301 had distinctly lower GI50
(Fig 4A and Appendix Table S2). To determine whether the
decrease in viable cells following IBL treatment was due to cell
death and not solely a result of decreased proliferation, we
analyzed the cell cycle distribution of neuroblastoma LU-NB-3
PDX cells. The fraction of cells in sub-G1 phase (i.e., non-viable
cells) increased after treatment, with the most profound induction
by the triple inhibitor IBL-301 (Fig 4B and C). We further showed
that the increase in cell death was mediated via apoptosis as
assessed by increased cleaved caspase-3 levels (Fig 4D) as well as
an increased fraction of Annexin V- and propidium iodide (PI)-
positive cells in PDXs and conventional neuroblastoma cell lines
(Fig 4E and F).
IBL-302 reduces neuroblastoma cell viability in vitro and tumor
growth in vivo
IBL-302, a compound with comparable structure to IBL-301, but
with increased bioavailability, was chosen for further testing. We
first reproduced in vitro data and confirmed that IBL-302 inhibited
downstream target activity (Fig 5A and B, and Appendix Fig S2A
and B). IBL-302 induced neuronal differentiation in PDX as well as
two neuroblastoma cell lines as assessed morphologically and
by quantification of neurite outgrowth (Fig 5C and D, and
Appendix Fig S2C). There was a concentration-dependent reduction
in N-Myc protein expression (Fig 5E). In similarity to previous data,
we observed reduced neuroblastoma cell viability at nanomolar
concentrations (Fig 5F). We could confirm that these changes were
due to induced cell death by the increased proportions of Annexin
V- and PI-positive cells (Fig 5G).
To assess how these results translated in vivo, we xeno-trans-
planted neuroblastoma cells into the flanks of immunodeficient
Nu/Nu mice. Mice were randomly allocated to either control or IBL-
302 groups (n = 5 in each group) and treated with IBL-302 per
orally (p.o.) 5 days a week. IBL-302-treated mice did not display
any signs of compound toxicity, and all maintained their body
weight throughout treatment (Appendix Fig S2D). Within a few days
of starting treatment, there were observable differences in tumor
growth, which increased throughout the experiment (Fig 5I). IBL-
302 markedly slowed tumor growth (Fig 5I and Appendix Fig S2E)



























PI3K α mTOR PIM1 PIM2 PIM3
IBL-301 2.5 134 18.2 13.6 3.17
IBL-302 2.08 81.3 22.8 7.74 5.86
IBL-202 10.1 4860 38.8 27.9 13.1
 
C
Figure 1. Structures of multikinase inhibitors.
A, B Chemical structures of IBL-301 (A) and IBL-302 (B).
C IC50 data of IBL-301, IBL-302, and IBL-202. IC50 values were calculated representing the percentage of inhibition against compound concentration and adjusting
the experimental data to sigmoidal curve using the software Activity base from IDBS.
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Anti-tumor effects from multikinase targeting
To investigate putative superior effects that triple kinase inhibition
holds over single-target inhibition, we set out to analyze the effect
of adding PIM and mTOR inhibitors to single inhibition of PI3K.
PI3K inhibitor PI-103, mTORC1/2 inhibitor PP242, and PIM inhi-
bitor AZD1208 were used alone or in combination. First, we estab-
lished EC50 values for all three single-target inhibitors in
neuroblastoma PDX cells (Fig EV3A–C), and these EC50 values
were used for subsequent combination analysis. There was a trend
toward increased neuroblastoma cell death following the combina-
tion of PI3K, mTORC1/2, and PIM inhibition as compared to
single-target inhibition (Fig EV3D and E). We expanded our analy-
sis on the effects of multikinase inhibition by comparing IBL-302
to PI3K inhibitors alone in neuroblastoma cell lines SK-N-AS and
SK-N-FI. Both PI3K inhibitors PI-103 and dactolisib induced a
A
B
Figure 2. Neuroblastoma is particularly sensitive to the multikinase inhibitor IBL-302.
A Screening of 707 cell lines from 47 tumor types for sensitivity against IBL-302. Tumor forms with n ≥ 5 cell lines screened are displayed. Comprehensive screening
data are available in Appendix Supplementary Materials. Horizontal bands are the median line; the upper part of the box is the 1st quartile and the lower box is the
3rd quartile; the error bars are the maximum and minimum values excluding outliers; the X symbols are mean values. The diagram should show that the y-axis is cut
at IC50 = 12, for visualization. Outliers range up to IC50 ~ 400.
B Screening of 16 neuroblastoma cell lines for sensitivity against IBL-302 vs. five PI3K only inhibitors.
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dose-dependent reduction in cell viability, although not as effi-
ciently as IBL-302 (Fig EV3F). We did however not observe any
significant differences in tumor growth in vivo between IBL-302
and dactolisib treatment when xeno-transplanting SK-N-AS cells
into Nu/Nu mice (Fig EV3G).
PIM/PI3K/mTOR inhibition potentiates the effect of
conventional chemotherapy
The majority of young neuroblastoma survivors experience later life































































































































Figure 3. PIM/PI3K/mTOR inhibition decreases N-Myc levels and increases cellular differentiation.
Neuroblastoma PDX and SK-N-BE(2)c cells treated with IBL inhibitors at indicated concentrations for 48 h.
A, B pAkt [at Ser473 (A) and Thr308 (B) sites] levels in LU-NB-3 and SK-N-BE(2)c cells determined by Western blotting. Total Akt levels were used as loading control.
C p-p70S6K and p-p85S6K levels in LU-NB-3 cells determined by Western blotting. Actin, p70S6K, and p85S6K levels were used as loading controls.
D Brightfield photomicrographs of LU-NB-3 and SK-N-BE(2)c cells treated with 0.36 lM IBL-202 or 0.05 lM IBL-301. Scale bars represent 100 lm (LU-NB-3) or
200 lm (SK-N-BE(2)c). Arrows indicate neurite outgrowths, and asterisks indicate where inserts are magnified. IBL-301-treated cells were stained for Tuj1. DAPI was
used to visualize nuclei.
E Quantification of neurite outgrowth presented as number of neurites/cell in LU-NB-3 PDX and SK-N-BE(2) cells treated with IBL-301. For LU-NB-3 PDX cells,
representative areas (n = 2) were used and n = 344 and n = 240 cells/condition for CTRL and IBL-301, respectively, were counted. For SK-N-BE(2)c cells, representative
areas (n = 2 and n = 3 for CTRL and IBL-301, respectively) were used and n = 141 and n = 130 cells/condition for CTRL and IBL-301, respectively, were counted. Values
are reported as mean  SEM. Statistical significance was determined by two-sided Student’s t-test. P = 0.003 for LU-NB-3 and P = 0.08 for SK-N-BE(2)c.
F Gap43 protein levels in LU-NB-3 and SK-N-BE(2)c cells determined by Western blotting. SDHA levels were used as loading control.
G N-Myc levels in LU-NB-2 and LU-NB-3 cells determined by Western blotting. SDHA levels were used as loading control.
Source data are available online for this figure.
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Adding IBL-202 or IBL-301 to cisplatin, a component of current
neuroblastoma therapy, demonstrated synergistic effects with regard
to cell viability (Fig 6A). IBL-302 showed an additive effect with
doxorubicin and etoposide, two further chemotherapies used in
neuroblastoma patients (Appendix Fig S3A and B). In the case of
cisplatin, concentrations of this chemotherapeutic could be reduced
by ~50% when combined with low-dose IBL-302, with retained
negative effects on cell viability (Fig 6B). Of note, IBL-302 and
cisplatin acted synergistically in reducing cell viability in LU-NB-3
PDX and SK-N-BE(2)c cells (Fig 6B). Possible synergistic effects of
IBL-302 and cisplatin are however not as clear in the SK-N-SH cells,
displaying additive as well as antagonistic effects depending on the
cisplatin concentration (Fig 6B). One possible explanation is that
LU-NB-3 and SK-N-BE(2)c cells are MYCN-amplified, while SK-N-SH
is a non-MYCN-amplified cell line. In line with the inhibitory effects
observed on N-Myc protein levels following IBL-302 treatment,
PIM/PI3K targeting might have a stronger effect against MYCN-
amplified neuroblastoma as compared to non-MYCN-amplified
tumors. As single-line treatments, IBL-302 and cisplatin slightly
increased the amount of neuroblastoma cells in the sub-G1 phase of
the cell cycle and when these two compounds were combined the
fraction of sub-G1 phase cells increased further (Fig 6C and D).
Triple kinase inhibitor IBL-302 potentiates the effects of cisplatin
in PDX models in vivo
To assess whether the effect of IBL-302 on cisplatin treatment
in vitro was also true in vivo, we xeno-transplanted LU-NB-3 PDX
cells into immunodeficient Nu/Nu mice and examined the growth-
inhibiting effect of combined IBL-302/cisplatin treatment. Mice were
allocated randomly to either control, IBL-302 alone, cisplatin alone,
or IBL-302 and cisplatin combination groups (n = 5 in each group).
Aiming to reduce the concentration of otherwise toxic cisplatin, we
treated mice with low-dose cisplatin as well as lower doses (50% of
maximum tolerated dose) of IBL-302. Again, treatment did not
induce any overt side effects in terms of either general mouse health
or body weight (Appendix Fig S3C).
There were no major differences in tumor growth between control
and low-dose IBL-302 (Fig 6E and F). In cisplatin-treated mice, there
were two response patterns: One group did not respond, whereas the
other partially responded in terms of reduced tumor growth (Fig 6E
and F). No mice in either of control, IBL-302 alone, or cisplatin alone
groups survived the study period (70 days; Fig 6E–G). However, in the
IBL-302/cisplatin combination group, there was a subgroup of partial
responders, similar to cisplatin alone, and two mice that substantially
responded to treatment, displaying slow or no growth and surviving
the study period (Fig 6E–G). There was a significant difference in
survival between the four treatment groups (P = 0.0014; Fig 6G).
Tumor sections from all four study groups were stained for the
expression of N-Myc protein. As expected, all tumors were N-Myc-
positive, but, of note, there was a decrease in nuclear N-Myc expres-
sion in tumors from the combination group (Fig 6H).
Global gene and protein analyses identify important IBL-302-
regulated biological processes
Since IBL-302 demonstrated effects on neuroblastoma PDX cells
in vitro and in vivo, we next investigated which biological processes
mediated these effects by treating PDX cells with nanomolar concen-
trations of IBL-302 and consequently performed RNAseq and mass
spectrometry analyses. Several cellular processes were influenced by
IBL-302, including cell motility, apoptosis, programmed cell death
(e.g., CASP3), and cell cycle (e.g., CDK6 and CCND1; Fig 7A–F and
Dataset EV1). Consistent with these data, caspase-3 and CDK6 were
among the most significantly differentially expressed proteins, being
upregulated by IBL-302 treatment as detected by mass spectrometry
(Fig 7E and F, and Dataset EV1).
To understand the relationship between IBL-302-induced RNA
and protein changes, we compared global gene and protein expres-
sion in each individual sample (control n = 4; IBL-302 n = 2). RNA
and protein expression levels were well-correlated (R > 0.50 in all
samples), suggesting that IBL-302 treatment significantly affects
both transcriptional and translational associated processes in
neuroblastoma (Figs 7G and EV4A). While correlations between
phosphorylated proteins and RNA expression were also robust
(R > 0.39 in all samples; Fig EV4B), the association between protein
and phosphorylated protein data was weaker (R ≤ 0.29; Fig EV4C).
Importantly, proteome (Fig 7E) and phospho-proteome (Fig 7F)
data identified several of the biological processes retrieved from the
RNAseq analysis (Fig 7D). Taken together, the RNA, protein, and
phospho-protein data show that the signaling of PIM, PI3K, and
mTOR seems to be of importance for regulating neuroblastoma cell
apoptosis.
Discussion
Constitutive activation or other alterations in the PI3K pathway are
certainly some of the most common aberrations in cancer (Engel-
man, 2009). Consequently, several PI3K inhibitors have reached
clinical trials and even the clinic (Fruman et al, 2017). Although
promising, some patients develop treatment resistance, in many
cases due to activation of parallel pathways that circumvent PI3K
inhibition and maintain tumor cell growth advantages. Activation of
the PIM kinases is thought to be an important PI3K inhibitor resis-
tance mechanism (Le et al, 2016). While little is known about the
◀ Figure 4. Treatment with multikinase inhibitors results in cell death.A Viability of IBL-202- or IBL-301-treated cells determined by CellTiter-Glo. Values are reported as mean  SEM. n = 2 replicates for LU-NB-2 and LU-NB-3, n = 3
replicates for SK-N-BE(2)c and SK-N-SH.
B, C Cell cycle distribution of LU-NB-3 cells determined by flow cytometry. Bars show mean values from two independent experiments.
D Cleaved caspase-3 (Cl Casp3) levels in LU-NB-3 cells determined by Western blotting. SDHA levels were used as loading control.
E Flow cytometry analyses of Annexin V and PI stainings following treatment with 360 nM IBL-202 or 50 nM IBL-301.
F Quantification of live and dead cells from the Annexin V/PI stainings. Dead cells = PI positive, live cells = PI negative. Dot plots from two independent experiments
and error bars represent SEM.
Source data are available online for this figure.
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role of PIM kinases in neuroblastoma, a recent report suggested that
PIMs might serve as prognostic biomarkers and putative treatment
targets in this tumor type (Brunen et al, 2018).
Here, we investigated the use of novel multikinase PIM/PI3K/
mTOR inhibitors in neuroblastoma treatment. Screening hundreds
of cell lines from nearly 50 tumor types confirmed that neuroblas-
toma was highly sensitive to triple kinase inhibition. We show that
the PIM/PI3K/mTOR inhibitors IBL-301 and IBL-302 induced
neuroblastoma cell differentiation and cell death at nanomolar
concentrations. Neuroblastomas presenting with a more differenti-
ated phenotype (i.e., high tumor cell expression of sympathetic
neuronal markers) are associated with less aggressive growth and a
lower risk of metastasis (Fredlund et al, 2008), and therapy that
induces sympathetic neuronal differentiation is a promising treat-
ment strategy. Triple PIM/PI3K/mTOR inhibition induced differenti-
ation of neuroblastoma cells, increasing the expression of the
sympathetic neuronal marker Gap43 and promoting neurite
outgrowth.
Amplification of the MYCN oncogene is present in ~25% of all
neuroblastomas and is a marker for aggressive tumors, and in line
with a differentiated phenotype, we detected lower N-Myc expres-
sion in our PDX cells following IBL-302 treatment. These findings
are consistent with previous reports on PI3K inhibition in neuroblas-
toma (Chesler et al, 2006; Johnsen et al, 2008; Chanthery et al,
2012; Cage et al, 2015). Similarly, PIM inhibition has previously
been suggested as a therapeutic option in MYC/MYCN-associated
tumor types (Kirschner et al, 2014; Horiuchi et al, 2016; Brunen
et al, 2018). Our results of combined PIM/PI3K inhibition effects in
neuroblastoma are in line with findings from other tumor types
including breast cancer (Le et al, 2016) and glioblastoma (Iqbal
et al, 2016). Future studies should address the design of optimal
drug combinations using IBL-302 with other targeted therapy and/
or chemotherapy for high-risk neuroblastoma.
Transcriptomic and proteomic analyses following PIM/PI3K/
mTOR inhibition confirmed our in vitro results and suggested that
IBL-302 treatment induces apoptosis, with caspase-3 being one of
the most differentially expressed genes/proteins as detected by both
RNA sequencing and mass spectrometry. In addition, cell cycle
regulation, differentiation, and cell migration processes were dysreg-
ulated following IBL-302 treatment. Protein and mRNA expression
strongly correlated in our datasets, suggesting that IBL-302 affects
both transcriptional and translational processes in neuroblastoma.
Emerging data suggest that high-risk neuroblastomas harbor a
high degree of intratumor heterogeneity and contain tumor
subclones with distinct genetic/epigenetic and/or phenotypic char-
acteristics (Eleveld et al, 2015; Mengelbier et al, 2015; Schramm
et al, 2015; Boeva et al, 2017; van Groningen et al, 2017; Braeke-
veldt et al, 2018; Karlsson et al, 2018). These findings suggest that
◀ Figure 5. IBL-302 reduces neuroblastoma growth in vivo.Neuroblastoma cells were treated with indicated concentrations of IBL-302 for 48 h (pAkt and N-Myc expression, photomicrographs, and flow cytometry) or 72 h (cell
viability, (F)).
A Expression of pAkt(Ser473) in LU-NB-3 and SK-N-BE(2)c cells. Total Akt and actin were used as loading controls.
B Expression of pAkt(Thr308) in LU-NB-3 and SK-N-BE(2)c cells. Total Akt and actin were used as loading controls.
C Brightfield photomicrographs of LU-NB-3 and SK-N-BE(2)c cells treated with 50 nM IBL-302. Scale bars represent 100 lm (LU-NB-3) or 200 lm (SK-N-BE(2)c).
D Quantification of neurite outgrowth presented as number of neurites/cell in LU-NB-3 PDX and SK-N-BE(2)c cells treated with IBL-302. For LU-NB-3 PDX cells,
representative areas (n = 4) were used and n = 460 and n = 216 cells/condition for CTRL and IBL-302, respectively, were counted. For SK-N-BE(2)c cells, representative
areas (n = 5 and n = 7 for CTRL and IBL-302, respectively) were used and n = 124 and n = 260 cells/condition for CTRL and IBL-301, respectively, were counted. Values
are reported as mean  SEM. Statistical significance was determined by two-sided Student’s t-test. P = 0.009 for LU-NB-3 and P = 0.0003 for SK-N-BE(2)c.
E N-Myc protein expression determined by Western blotting. SDHA was used as loading control.
F Cell viability determined by CellTiter-Glo. Values are reported as mean  SEM. n = 3.
G Flow cytometry analyses of Annexin V and PI stainings following treatment with 50 nM IBL-302.
H Quantification of live and dead cells. Dead cells = PI positive, live cells = PI negative. Dot plots from two independent experiments and error bars represent SEM.
I Neuroblastoma SK-N-BE(2)c carrying mice (n = 5 in each group) were treated with vehicle (CTRL) or 40 mg/kg IBL-302 for up to 35 days, and tumor growth was
followed over time. Asterisks indicate each occasion a mouse within that particular group was sacrificed. Values are reported as mean  SEM.
J Kaplan–Meier survival curves comparing mice treated with vehicle (CTRL) or IBL-302. Log-rank test was used to determine statistical significance. P = 0.0577. n = 5 in
each group.
Source data are available online for this figure.
▸Figure 6. PIM/PI3K/mTOR inhibition enhances the effects of chemotherapy.A, B LU-NB-3 PDX, SK-N-BE(2)c, and SK-N-SH cells were treated with indicated concentrations of cisplatin and/or 0.36 lM IBL-202, 0.05 lM IBL-301, or 0.05 lM IBL-302
for 48 h. Cell viability determined by CellTiter-Glo. Graphs show mean values and SEM from three independent experiments. Theoretical additive curves were
evaluated by calculating the combination index (CI) based on the Bliss independence model.
C, D Cell cycle distribution in LU-NB-3 PDX cells after treatment with 320 nM cisplatin, 50 nM IBL-302, or the combination of these, determined by flow cytometry. Bars
show mean values from two independent experiments.
E Tumor size in individual mice from (F.) presented as each group separately.
F Neuroblastoma PDX carrying mice (n = 5 in each group) were treated with vehicle (CTRL), low-dose (20 mg/kg) IBL-302, low-dose (1 mg/kg) cisplatin, or the
combination of low-dose IBL-302 and low-dose cisplatin for up to 70 days. Tumor size was measured over time. Asterisks indicate each occasion a mouse within
that particular group was sacrificed. Values are reported as mean  SEM.
G Kaplan–Meier survival curves comparing mice treated with vehicle (CTRL), IBL-302, cisplatin, or the combination. Log-rank test was used to determine statistical
significance. P = 0.0014. n = 5 per group.
H Immunohistochemical staining of N-Myc expression in tumors from (F). Scale bars represent 100 lm. Roman numbers in each box indicate which mouse the
tumor derives from (see individual graphs in E).
Source data are available online for this figure.
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general and/or combinatorial therapeutic strategies must be
further explored. Our combined PIM/PI3K/mTOR inhibition is a
viable treatment strategy for neuroblastoma. We also show that
the combination of low-dose IBL-302 (50% of maximum tolerated
dose) and low-dose cisplatin suppressed neuroblastoma growth in
PDX in vivo models. These findings represent a novel promising
approach for children with high-risk MYCN-amplified neuroblas-




The kinase activity of PI3K alpha was measured by using the
commercial ADP HunterTM Plus assay (DiscoveRx), a homogeneous
assay measuring ADP accumulation, as a universal product of
kinase activity. The assay was done following general manufacturer
recommendations and adapting protein and substrate concentra-
tions to optimal conditions. Kinase buffer was 50 mM HEPES, pH
7.5, 100 mM NaCl, 1 mM EGTA, 0.04% CHAPS, 3 mM MgCl2, and
10 lg/ml BGG (bovine c-globulin), 2 mM TCEP. The assay was
done at 100 lM PIP2, as peptide substrate, and 50 lM ATP. Protein
concentration was 0.8 ng/ll. In order to calculate the IC50 of
described compounds, serial 1:5 dilutions were prepared, and the
reaction started by the addition of ATP. Incubation was done for 1 h
at 25°C. Reagents A and B (DiscoveRx) were sequentially added to
the wells, and plates were incubated for 30 min at 37°C. Fluores-
cence counts were read in a Victor instrument (PerkinElmer) with
the recommended settings (544 and 580 nm as excitation and emis-
sion wavelengths, respectively). Values were plotted against inhi-
bitor concentration and fit to a sigmoid dose–response curve with
the GraphPad software.
mTOR biochemical assay
The biochemical assay to measure mTOR activity relies on the
LanthaScreenTM kinase activity assay (Invitrogen), where kinase,
GFP-labeled substrate, and ATP are allowed to react. EDTA (to stop
the reaction) and terbium-labeled antibody (to detect phosphory-
lated product) are then added. In a LanthaScreenTM kinase reaction,
the antibody associates with the phosphorylated GFP-labeled
substrate resulting in an increased TR-FRET value. The TR-FRET
value is a dimensionless number that is calculated as the ratio of the
acceptor (GFP) signal to the donor (terbium) signal. The amount of
antibody that is bound to the tracer is directly proportional to the
amount of phosphorylated substrate present, and in this manner,
kinase activity can be detected and measured by an increase in the
TR-FRET value.
The mTOR enzyme has been purchased from Invitrogen
mTOR, as well as the GFP-labeled substrate (4EBP1-GFP) and the
Tb-anti-p4EBP1 (pThr46) antibody. Assay conditions were as indi-
cated by the kit manufacturers. Assays were performed in 96-well
plates. The final read out was generated using an EnVision plate
reader (PerkinElmer) The TR-FRET value (a dimensionless number)
was calculated as the ratio of the acceptor signal (GFP, emission at
520 nm) to the donor signal (terbium, emission at 495 nm). Values
were plotted against the inhibitor concentration and fitted to a
sigmoid dose–response curve using GraphPad software.
PIM kinase assays
The PIM kinase activities were measured using the commercial ADP
HunterTM Plus assay (DiscoveRx), a homogeneous assay measuring
ADP accumulation, as a universal product of kinase activity. The
assay was done following general manufacturer recommendations
and adapting protein and substrate concentrations to optimal condi-
tions. Kinase buffer was 15 mM HEPES, pH 7.4, 20 mM NaCl,
1 mM EGTA, 0.02% Tween-20, 10 mM MgCl2, and 0.1 mg/ml
LBGG (bovine c-globulin). All PIM kinase assays were done at
100 lM PIMtide (ARKRRRHPSGPPTA), as peptide substrate, and
100 lM ATP. Protein concentration was 50, 350, and 500 ng/ll for
PIM1, PIM2, and PIM3, respectively. In order to calculate the IC50 of
described compounds, serial 1:5 dilutions were prepared, and the
reaction started by the addition of ATP. Incubation was done for 1 h
at 25°C. Reagents A and B (DiscoveRx) were sequentially added to
the wells, and plates were incubated for 30 min at 37°C. Fluores-
cence counts were read in a Victor instrument (PerkinElmer) with
the recommended settings (544 and 580 nm as excitation and emis-
sion wavelengths, respectively). Values were plotted against inhi-
bitor concentration and fit to a sigmoid dose–response curve with
the GraphPad software.
Patient samples
PDX samples were previously established and have been
described in detail (Braekeveldt et al, 2015; Persson et al, 2017).
LU-NB-2 cells were derived from a brain metastasis following
chemotherapy relapse (Stage IV; patient age 2y2m). LU-NB-3 cells
were derived from an untreated primary tumor in the adrenal
gland (Stage III; patient age 2y9m). LU-NB-2 and LU-NB-3 were
◀ Figure 7. Tumor-related processes are affected by IBL-302 treatment.LU-NB-3 PDX cells were treated with 50 nM of IBL-302 for 48 h and subsequently analyzed by RNAseq and mass spectrometry.
A–C Heat map of significantly differentially expressed genes across treatment groups from RNAseq data (FDR < 0.1) (A). Genes defined as differentially expressed that
were also present in MS and phospho-MS are visualized in (B) and (C), respectively.
D Gene ontology generated from significantly altered genes from RNAseq data. log(P-values) and percent of input gene/protein lists that overlap with the specified
ontology are displayed.
E Gene ontology generated from significantly altered proteins from mass spectrometry proteome data. log(P-values) and percent of input gene/protein lists that
overlap with the specified ontology are displayed.
F Gene ontology generated from significantly altered phospho-proteins from mass spectrometry phospho-proteome data. log(P-values) and percent of input gene/
protein lists that overlap with the specified ontology are displayed.
G Cross-platform sample correlations of RNAseq and mass spectrometry proteome data. Pearson’s correlation coefficients are displayed.
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cultured as described previously (Persson et al, 2017). Briefly,
PDX-derived cells were maintained in a mix of Dulbecco’s modi-
fied Eagle’s medium (DMEM) and GlutaMAXTM F-12 (3:1 ratio)
supplemented with 1% penicillin/streptomycin (P/S), 2% B27 w/o
vitamin A, 40 ng/ml basic fibroblast growth factor (FGF), and
20 ng/ml epidermal growth factor (EGF), with no addition of FBS.
For adherent growth purposes, PDX-derived cells were grown on
laminin-coated wells (10 lg/ml laminin-521, Biolamina). All cells
in culture were regularly replaced and screened for mycoplasma.
Cell authentication was performed through SNP profiling of PDX-
derived cell lines and their corresponding PDXs (Multiplexion,
Heidelberg, Germany).
Cell lines
The human SK-N-BE(2)c (CRL-2268; a kind gift from Dr. June
Biedler), SK-N-SH, SK-N-FI, and SK-N-AS cell lines were acquired
from ATCC. Neuroblastoma cells were cultured in minimal essential
medium (MEM; SK-N-BE(2)c and SK-N-SH) or RPMI (SK-N-FI and
SK-N-AS) supplemented with fetal bovine serum (FBS) and P/S. All
cells in culture were regularly replaced and screened for myco-
plasma. Cell authentication was performed through SNP profiling
(Multiplexion, Heidelberg, Germany).
Screening
Publicly available data on GI50 values for omipalisib, AZD8055,
SL0101, PI-103, and dactolisib across a panel of 16 neuroblastoma
cell lines were obtained from the Genomics of Drug Sensitivity in
Cancer (GDSC) database (Yang et al, 2013; Release 7.0). GI50 data
for IBL-302 across 707 cell lines from 47 tumor types and across a
separate panel of 16 neuroblastoma cell lines were obtained from
the GDSC consortium (Yang et al, 2013).
Reagents
Multikinase inhibitors IBL-202 (PIM/PI3K), IBL-301 (PIM/PI3K/
mTOR), and IBL-302 (PIM/PI3K/mTOR) were reconstituted in
100% DMSO for in vitro experiments and used at concentrations
surrounding the GI50 range for respective drug (0–2.16 lM for
IBL-202; 0–1.28 lM for IBL-301; 0–1.0 lM for IBL-302). When
fixed concentrations of the IBL inhibitors were used in vitro,
these were chosen based on viability assays as lowest possible
dose but with viable effects. For in vivo experiments, IBL-302
was reconstituted in either DMSO:PEG400 (10:90 v/v) or DMSO:
PEG400:vitamin E TPGS (10:70:20 v/v) and administered at 40 or
20 mg/kg p.o five times a week. Chemotherapeutic drugs
cisplatin, doxorubicin, and etoposide were diluted in sterile H2O
and used at concentrations as indicated in in vitro experiments
(0–5 lM for cisplatin; 0–50 nM for doxorubicin; 0–160 nM for
etoposide). For in vivo treatment, cisplatin was reconstituted in
sterile saline and administered at 1 mg/kg intraperitoneally (i.p)
three times a week. Vehicle controls were DMSO for in vitro
experiments and DMSO:PEG400 or DMSO:PEG400:vitamin E TPGS
for in vivo experiments. Inhibitors dactolisib, PI-103, AZD1208,
and PP242 were diluted in 100% DMSO for in vitro work, and
dactolisib was diluted in 10% DMSO and 90% PEG400 for
in vivo work.
RNA extraction and qRT–PCR
Total RNA was automatically extracted using the Arrow with Arrow
RNA (Tissue Kit-DNA Free) Kit (DiaSorin, Saluggia, Italy) and
converted to cDNA using the MultiScribe Reverse Transcriptase
Enzyme (Applied Biosystems, Foster City, CA) with random
primers. Quantitative RT–PCR was performed with the SYBR Green
PCR Master Mix (Life Technologies, Carlsbad, CA) using the
comparative Ct method (Vandesompele et al, 2002). Three reference
genes (YWHAZ, UBC, and SDHA) were used to normalize gene-of-
interest expression. Primer sequences can be found in
Appendix Table S3.
Western blot
Cells were lysed in RIPA buffer supplemented with Complete
Protease Inhibitor (Roche, Basel, Switzerland) and phosSTOP
(Roche) as previously described (Mohlin et al, 2015). Proteins were
separated on SDS–PAGE gels and transferred to PVDF- or Hybond-C
extra nitrocellulose membranes (Bio-Rad, Hercules, CA). Antibodies
are listed in Appendix Table S4.
Immunofluorescence
Adherent SK-N-BE(2)c cells were cultured and treated on presteril-
ized cover slips, whereas PDX-derived cells were grown on
precoated laminin-covered (10 lg/ml laminin-521, Biolamina) glass
slides. All cells were fixed in 4% paraformaldehyde before antibody
blocking and cell membrane permeabilization in 5% goat serum
and 0.5% Triton-X. Staining of peripheral neurons was performed
using the mouse monoclonal anti-human Tuj1 antibody [Covance
(MMS-435P), Princeton, NJ; 1:500], and positive cells were visual-
ized by Alexa Fluor 488 goat anti-mouse antibody [Invitrogen
(A11029), 1:200]. Cell nuclei were visualized by DAPI staining
[Invitrogen (D3571), 1:3,000].
Cell viability assay
Cells were seeded in triplicates in white opaque 96-well plates,
5,000 cells per well. SK-N-BE(2)c, SK-N-SH, SK-N-AS, and SK-N-FI
cells were incubated for 24 h before treatment, while the PDX-
derived cells LU-NB-2 and LU-NB-3 were treated directly after seed-
ing. Treated cells were incubated for 48 or 72 h, and cell viability
was measured using the CellTiter-Glo assay (G7571; Promega,
Madison, WI).
Annexin V
Cell death was evaluated through Annexin V and PI staining.
Treated cells were stained with 5% APC Annexin V and 2% propid-
ium iodide (PI). The samples were incubated for 15 min and then
run on a FACSVerse flow cytometer (BD Biosciences). The data
were analyzed using the FlowJo software.
Cell cycle distribution
Cells were treated for 48 h and then fixed in ice-cold 70% ethanol.
Samples were kept at 20°C and upon analysis washed in PBS and
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incubated on ice for 45 min in Vindelöv solution [3.5 lmol/l Tris–HCl
(pH 7.6), 10 mmol/l NaCl, 50 lg/ml propidium iodide, 20 lg/ml
RNase, 0.1% v/v NP40]. Samples were run on a FACSVerse flow
cytometer (BD Biosciences, Franklin Lakes, NJ), and the data were
analyzed using the FlowJo software.
Chemotherapy combination experiments
Cells were seeded in triplicates in white opaque 96-well plates,
5,000 cells per well. Cells were incubated for 24 h before being
treated for 48 h using log-scale concentrations of chemotherapeu-
tic in addition to fixed concentrations of IBL compounds as indi-
cated. Cell viability was measured with CellTiter-Glo as
previously described, and data were normalized to the average
of all treated wells with DMSO. All synergy experiments were
performed as technical triplicates. Potential synergy between
chemotherapeutics and IBL compounds was evaluated by calcu-
lating the combination index (CI) based on the Bliss indepen-
dence model (Foucquier & Guedj, 2015), whereby the CI was
calculated with the following equation: CI ¼ EaþEbEaEb
Eab
, where
Ea indicates the viability effect of drug A (chemotherapeutic), Eb
indicates the viability effect of drug B (IBL compound), and Eab
indicates the viability effect of the drug combination. CI < 1 indi-
cates synergism, CI = 1 indicates additivity, and CI > 1 indicates
antagonism.
In vivo experiments
Four- to eight-week-old female athymic mice (NMRI-Nu/Nu) were
purchased from Taconic. The regional ethics committee approved
all procedures (ethical permits M11-15 and M146-13) and housing
facilities comply with official regulations. Animals’ general health
conditions were checked daily by professional caretakers. Female
mice were kept in groups of up to five in standard IVC cages
containing bedding and nesting material. Mice were under
controlled lighting conditions (12-h light cycles), relative humidity
and temperature, food, and water provided ad libitum. All efforts
were made to minimize animal suffering and reduce the number
of animals sacrificed. One million SK-N-BE(2)c or LU-NB-3 cells
were diluted in culture medium:matrigel solution (2:1) and
injected subcutaneously into the right flank of the mice. Tumor
volume was measured three times a week using a digital caliper
and calculated with the formula V = pls2/6 (l = long side;
s = short side). For the SK-N-BE(2)c study, mice were randomly
allocated into one of two groups (control or IBL-302, respectively,
n = 5 in each group) 11 days after tumor cell injection (average
tumor size in each group ~110 mm3). Mice were treated p.o.
5 days a week with 40 mg/kg IBL-302 diluted in 10% DMSO and
90% PEG-400 or the corresponding amount of vehicle. Mice were
treated until individual tumor sizes had reached ~1,800 mm3. For
the LU-NB-3 PDX study, mice were allocated individually when
their respective tumors had reached a minimum size of 100 mm3
(average size in each group ~240 mm3) into one of four groups:
control, IBL-302, cisplatin, or IBL-302 and cisplatin combination
(n = 5 in each group). Mice were treated p.o. 5 days a week
with 20 mg/kg IBL-302 diluted in 10% DMSO, 20% vitamin E,
and 70% PEG400 and/or i.p. 3 days a week with 1 mg/kg
cisplatin diluted in saline. Corresponding amounts of 10% DMSO,
20% vitamin E, and 70% PEG400 served as vehicle control for
all groups. Mice were treated until their individual tumor size
had reached ~1,800 mm3 or after a maximum of 50 injection
days.
For the IBL-302 and dactolisib comparison study, three million
SK-N-AS cells were injected subcutaneously and after 10 days
mice were allocated to one of three groups: control DMSO/PEG400
10/90), dactolisib (45 mg/ml), or IBL-302 (40 mg/kg). All mice
were treated 5 days per week (Monday to Friday) using i.p. injec-
tions. Mice were euthanized when their tumor size had reached
~1,800 mm3 or at the end of the study.
Immunohistochemistry
Dissected tumors from in vivo studies were fixed in 4%
paraformaldehyde and embedded in paraffin. After antigen retrieval
using PT Link (Dako; Agilent Technologies, Santa Clara, CA),
sections (4 lm) were stained using the Autostainer Plus (Dako).
Antibodies used can be found in Appendix Table S4.
RNA sequencing
LU-NB-3 cells were seeded on laminin precoated plates (10 lg/ml
laminin-521, Biolamina) and allowed to attach for 24 h. Cells
were treated with 50 nM IBL-302 or vehicle control for 48 h
before harvesting. Each sample consisted of pooled cells from
plates treated equally, and samples were then divided into
aliquots intended for RNAseq (five samples control; five samples
IBL-302), mass spectrometry (see separate section), and Western
blot verification. RNA was prepared using Ion AmpliSeqTM Tran-
scriptome Human Gene Expression Kit Preparation protocol and
sequenced on the Ion ProtonTM System using the Ion PITM Hi-Q
Sequencing 200 Kit chemistry (200 bp read length, Thermo
Fisher), as described in Braekeveldt et al (2018). Counts were
normalized relative to total counts per sample, and the data were
analyzed using the R2: Genomic Analysis and Visualization Plat-
form (http://r2.amc.nl).
Mass spectrometry
LU-NB-3 cells were seeded on laminin precoated plates (10 lg/ml
laminin-521, Biolamina) and allowed to attach for 24 h. Cells were
treated with 50 nM IBL-302 or vehicle control for 48 h before
harvesting. Each sample consisted of pooled cells from plates
treated equally, and samples were then divided into aliquots
intended for RNAseq (see separate section), mass spectrometry
(four samples control; three samples IBL-302), and Western blot-
ting. A detailed description of the mass spectrometry analyses can
be found in Appendix Supplementary Methods.
Statistics
All values are reported as mean  SEM from n independent biologi-
cal experiments, where n is depicted in each figure. The two-sided
Student’s unpaired t-test was used for statistical analyses between
two groups, while one-way ANOVA was used for statistical analyses
between three groups or more. Three levels of significance were
used: *P < 0.05; **P < 0.01; and ***P < 0.001. Publicly available
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datasets containing 88 and 498 neuroblastomas, respectively (R2:
microarray analysis and visualization platform; http://r2.amc.nl),
were used to analyze gene expression and overall survival. Kaplan–
Meier survival analyses for in vivo studies were generated using
GraphPad Prism version 7.0c. Statistical significance was calculated
using the log-rank test.
Study approval
NMRI-Nu/Nu mice were housed in a controlled environment. The
regional ethics committee approved all procedures (ethical permits
M11-15 and M146-13).
Data availability
The mass spectrometry proteomic data have been deposited to the
ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al,
2019) partner repository with the dataset identifier PXD014234
(https://www.ebi.ac.uk/pride/archive/projects/PXD014234).
The RNA sequencing data discussed in this publication have
been deposited in NCBI’s Gene Expression Omnibus (Edgar et al,
2002) and are accessible through GEO Series accession number
GSE133137 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=
GSE133137), and were analyzed using the R2: Genomics Analysis
and Visualization Platform (http://r2.amc.nl).
Expanded View for this article is available online.
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